{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:35:19Z","timestamp":1791876919638,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clml.2025.09.015","type":"journal-article","created":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T15:22:55Z","timestamp":1759072975000},"page":"e315-e324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1177-2573","authenticated-orcid":false,"given":"Ishita","family":"Kamboj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1882-0504","authenticated-orcid":false,"given":"Andrew","family":"Vegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Struble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8122-0563","authenticated-orcid":false,"given":"Muhammad Umair","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-2521","authenticated-orcid":false,"given":"Zahra","family":"Mahmoudjafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2166-2583","authenticated-orcid":false,"given":"Abdullah Mohammad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Sun","family":"Strouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5604-4166","authenticated-orcid":false,"given":"Hira","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-7534","authenticated-orcid":false,"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-4982","authenticated-orcid":false,"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clml.2025.09.015_bib0001","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2025.09.015_bib0002","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.clml.2025.09.015_bib0003","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2025.09.015_bib0004","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.09.015_bib0005","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med."},{"issue":"10297","key":"10.1016\/j.clml.2025.09.015_bib0006","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clml.2025.09.015_bib0007","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2025.09.015_bib0008","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Fern\u00e1ndez de Larrea C. development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma","volume":"42","author":"Gagelmann","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.09.015_bib0009","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.09.015_bib0010","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","article-title":"Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes","volume":"17","author":"Shah","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.09.015_bib0011","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/EDBK_156686","article-title":"The role of clinical trial participation in cancer research: barriers, evidence, and strategies","volume":"35","author":"Unger","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"8","key":"10.1016\/j.clml.2025.09.015_bib0012","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.clml.2025.09.015_bib0013","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.09.015_bib0014","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","article-title":"High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions","volume":"12","author":"Hagen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.clml.2025.09.015_bib0015","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2025.09.015_bib0016","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.clml.2025.09.015_bib0017","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2025.09.015_bib0018","first-page":"71","article-title":"The antibody drug conjugate, belantamab-mafodotin, in the treatment of multiple myeloma: a comprehensive review","volume":"14","author":"Almodovar Diaz","year":"2024","journal-title":"Blood Lymphat Cancer"},{"issue":"10","key":"10.1016\/j.clml.2025.09.015_bib0019","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-020-00369-0","article-title":"Single-agent belantamab mafodotin for relapsed\/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study","volume":"10","author":"Richardson","year":"2020","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2025.09.015_bib0020","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.09.015_bib0021","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1182\/blood-2021-146047","article-title":"SEA-BCMA, an investigational nonfucosylated monoclonal antibody: ongoing results of a phase 1 study in patients with relapsed\/refractory multiple myeloma (SGNBCMA-001)","volume":"138","author":"Hoffman","year":"2021","journal-title":"Blood"},{"issue":"17_suppl","key":"10.1016\/j.clml.2025.09.015_bib0022","doi-asserted-by":"crossref","first-page":"LBA106","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA106","article-title":"First phase 3 results from CARTITUDE-4: cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma","volume":"41","author":"Dhakal","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.09.015_bib0023","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Einsele H. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2025.09.015_bib0024","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2025.09.015_bib0025","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","article-title":"Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing","volume":"12","author":"Li","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.09.015_bib0026","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2023012066","article-title":"Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma","volume":"8","author":"Reyes","year":"2024","journal-title":"Blood Adv"},{"issue":"33","key":"10.1016\/j.clml.2025.09.015_bib0027","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2017.74.4102","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research organ dysfunction, prior or concurrent malignancy, and comorbidities working group","volume":"35","author":"Lichtman","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.09.015_bib0028","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.3390\/curroncol31070275","article-title":"What is ailing oncology clinical trials? Can we fix them?","volume":"31","author":"Mittal","year":"2024","journal-title":"Curr Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.09.015_bib0029","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.09.015_bib0030","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clml.2025.09.015_bib0031","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.6004\/jnccn.2020.7673","article-title":"Defining and managing high-risk multiple myeloma: current concepts","volume":"18","author":"Costa","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.clml.2025.09.015_bib0032","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.09.015_bib0033","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.09.015_bib0034","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00018-005-5390-y","article-title":"Glucocorticoids in T cell apoptosis and function","volume":"63","author":"Herold","year":"2006","journal-title":"Cell Mol Life Sci"},{"issue":"35","key":"10.1016\/j.clml.2025.09.015_bib0035","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.09.015_bib0036","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/biom13020382","article-title":"Early use of corticosteroids following CAR T-cell therapy correlates with reduced risk of high-grade CRS without negative impact on neurotoxicity or treatment outcome","volume":"13","author":"Lakomy","year":"2023","journal-title":"Biomolecules"},{"issue":"24","key":"10.1016\/j.clml.2025.09.015_bib0037","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1182\/blood.2019003618","article-title":"The earlier the better: timely mitigation of CRS","volume":"134","author":"Rouce","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.09.015_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285125","article-title":"RWD-derived response in multiple myeloma","volume":"18","author":"Xu","year":"2023","journal-title":"PLoS One"},{"issue":"15_suppl","key":"10.1016\/j.clml.2025.09.015_bib0039","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e19260","article-title":"Assessing real-world clinical response in patients with multiple myeloma (MM): a survey of the literature","volume":"38","author":"Lane","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.09.015_bib0040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2025.09.015_bib0041","first-page":"3398","article-title":"Timing of toxicities and non-relapse mortality following CAR T therapy in myeloma","volume":"12","author":"Wesson","year":"2024","journal-title":"J Transl Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2025.09.015_bib0042","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/hematology.2024000534","article-title":"Late complications and long-term care of adult CAR T-cell patients","volume":"2024","author":"Bishop","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.09.015_bib0043","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1182\/blood-2024-201783","article-title":"Delayed neurotoxicity after CAR-T in multiple myeloma: results from a global IMWG registry","volume":"144","author":"Kumar","year":"2024","journal-title":"Blood."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:45:01Z","timestamp":1780991101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2152265025042260"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}